Clostridium difficile Infection in Intestinal Transplant Recipients.
1Medicine, Infectious Diseases, University of Miami Miller School of Medicine, Miami, FL
2Medicine, University of Miami Miller School of Medicine, Miami, FL
Meeting: 2017 American Transplant Congress
Abstract number: B90
Keywords: Bacterial infection, Infection, Intestinal transplantation, Outcome
Session Information
Session Name: Poster Session B: Bacteria, Fungi, Parasites
Session Type: Poster Session
Date: Sunday, April 30, 2017
Session Time: 6:00pm-7:00pm
Presentation Time: 6:00pm-7:00pm
Location: Hall D1
Background: Clostridium difficile infection (CDI) data in intestinal transplant (ITx) recipients is lacking. This study was performed to evaluate prevalence, risk factors, treatments and outcomes of CDI in ITx recipients.
Methods: Retrospective study of adult and pediatric patients who underwent ITx (isolated or multi-visceral) between 1/2013 and 12/2015 at Jackson Memorial Hospital. Those who developed CDI within a year after ITx were considered cases. We evaluated if there were any differences in demographics, antibiotics or proton-pump inhibitors (PPI) use within 90 days prior and after ITx and one-year posttransplant survival between cases and controls. In addition, we assessed for severe CDI (WBC >15×103/mcl, creatinine >1.5 x baseline or pseudomembranes), CDI treatments and outcomes.
Results: 10/51 (20%) ITx recipients developed CDI. There were no differences in demographics, antibiotics or PPI use and one-year survival between groups [Table1]. The mean time from ITx to CDI diagnosis was 209±88.9 days. Four cases were severe. Vancomycin was given to two patients, and metronidazole and combined metronidazole/vancomycin to four each. None had colectomy, died from CDI or had recurrences within 12 weeks after being treated for CDI.
Conclusions: CDI was common in our ITx recipients and it was not associated with adverse outcomes. Larger studies are needed.
| Variables | CDI-pos
N[ordm] 10 (%) |
CDI-neg
N[ordm] 41 (%) |
P-value |
| Age (years) | 26.7±22.3 | 29.3±23.4 | 0.75 |
| Gender (female) | 4(40) | 22(54) | 0.50 |
| Antibiotic exposure | 10(100) | 39(95) | >0.99 |
| Quinolones | 2(20) | 12(29) | 0.71 |
| Clindamycin | 1(10) | 2(5) | 0.49 |
| 3rdand 4thgeneration cephalosporins | 8(80) | 30(73) | >0.99 |
| Carbapenems | 5(50) | 21(51) | 0.94 |
| Beta-lactamase inhibitors | 4(40) | 19(46) | >0.99 |
| Aztreonam | 0 | 2(5) | >0.99 |
| Tigecycline | 1(10) | 3(7) | >0.99 |
| Number of days of antibiotics | 31.6±11.3 | 50.4±41 | 0.16 |
| ≥ 2 groups of antibiotics | 7(70) | 27(66) | >0.99 |
| PPI | 9(90) | 40(98) | 0.36 |
| Survival at one-year posttransplant | 10(100) | 30(73) | 0.09 |
CITATION INFORMATION: Goldenberg V, Berbel A, Camargo J, Simkins J. Clostridium difficile Infection in Intestinal Transplant Recipients. Am J Transplant. 2017;17 (suppl 3).
To cite this abstract in AMA style:
Goldenberg V, Berbel A, Camargo J, Simkins J. Clostridium difficile Infection in Intestinal Transplant Recipients. [abstract]. Am J Transplant. 2017; 17 (suppl 3). https://atcmeetingabstracts.com/abstract/clostridium-difficile-infection-in-intestinal-transplant-recipients/. Accessed May 9, 2025.« Back to 2017 American Transplant Congress